---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-005085"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2024-02-06T23:59:59+00:00"
generated_at: "2026-06-06T08:18:13.899129+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AgeX draws $500k note, converts preferred shares giving Juvenescence 75.6% control, extends Serina merger deadline

## Summary
- Drew $500,000 under secured convertible note with Juvenescence; repayment due Feb 14, 2024.
- Converted 211,600 Series A and 148,400 Series B preferred shares into 50M common shares for Juvenescence.
- Juvenescence now holds 66.4M shares (75.6% of outstanding); change in control of AgeX deemed to have occurred.
- Merger agreement with Serina extended to April 29, 2024; Juvenescence entered support agreement to vote in favor.
- Post-merger, Serina holders expected to own ~75% of combined company; AgeX holders ~25%.

## SEC filing metadata
- accession: 0001493152-24-005085
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2024-02-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.03, 3.02, 5.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000149315224005085/0001493152-24-005085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000149315224005085/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-005085
- JSON: https://secwatch.observer/filing/0001493152-24-005085.json
- Plain text: https://secwatch.observer/filing/0001493152-24-005085.txt

## Key facts
- Debt Financings
  Serina Therapeutics, Inc. incurred convertible notes of $500,000 with Juvenescence Limited maturing February 14, 2024.
  - Instrument: convertible notes
  - Principal: $500,000
  - Counterparty: Juvenescence Limited
  - Maturity: February 14, 2024
  - Event: incurrence
  source text: On February 1, 2024, AgeX Therapeutics, Inc. (“AgeX”) drew $500,000 of its credit available under the Amended and Restated Secured Convertible Promissory Note (as amended, the “Secured Note”) with Juvenescence Limited (“Juvenescence”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000149315224005085/0001493152-24-005085-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.